Ibrance now FDA-approved to treat advanced breast cancer

Share this content:
US Food and Drug Administration
US Food and Drug Administration

(HealthDay News) -- Ibrance (palbociclib) has been approved by the U.S. Food and Drug Administration to treat advanced breast cancer among postmenopausal women.

Ibrance inhibits molecules that spur the growth of cancer cells. The drug is sanctioned for postmenopausal women with estrogen receptor-positive, human epidermal growth factor 2-negative metastatic breast cancer who haven't been given an endocrine-based therapy, the FDA said. It's meant to be given in combination with Femara (letrozole).

Ibrance's effectiveness was evaluated among 165 postmenopausal women with this form of breast cancer. Those treated with Ibrance and letrozole lived about 20.2 months without disease progression, compared with about 10.2 months among women given only letrozole, the FDA said.

The most common side effects of Ibrance included neutropenia, fatigue, anemia, upper respiratory infection, nausea, hair loss, diarrhea, thrombocytopenia, loss of appetite, nerve damage, and epistaxis. Doctors should tell potential users of these risks, the FDA advised.

Ibrance is marketed by Pfizer, based in New York City.

More Information

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs